Loading data for IMA — first visit, this takes a few seconds.
ImageneBio, Inc. (IMA)
NasdaqCM: IMA
· Real-Time Price · USD
5.34
+0.01 (0.19%)
At close: Sep 01, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
ImageneBio, Inc. (IMA) Stock Price, Analysis & Data
No data available
| Bid | 3.78 |
| Market Cap | 57.1M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -53.3M |
| 0.00 | |
| -4.61 | |
| n/a | |
| -1.16 | |
| P/B (ttm) | 0.40 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 5.39 |
| Volume | 4,509 |
| Avg. Volume (20D) | 11,962 |
| Open | 5.35 |
| Previous Close | 5.33 |
| Day's Range | 5.32 - 5.35 |
| 52-Week Range | 3.94 - 13.98 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMA
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its nam...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 18
Stock Exchange NasdaqCM
Ticker Symbol IMA
Website https://www.inmagenebio.com
Financial Performance
In 2025, ImageneBio's revenue was 800K, a decrease of -77.14% compared to the previous year's 3.5M. Earnings were -45.35M, an increase of 24.01%.
Financial StatementsEarnings Surprise
ImageneBio has released their quarterly earnings on Aug 5, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.63 exceeds estimates by 0.35, with -Infinity% YoY decline.
